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Background: The development of collateral arteries after a myocardial infarction (MI) was intensively 2 
studied, while the mechanism by which pericytes (PCs) contribute to arteriologenesis remains 3 
unexplored. This study aimed to 1) investigate if cardiac PCs gain functional features of contractile 4 
vascular smooth muscle cells (VSMCs) in vitro, and 2) determine if this potential can be evoked 5 
pharmacologically to encourage heart arteriologenesis in vivo. 6 
Methods: PCs were immunosorted as CD31neg/CD34pos cells from human and mouse hearts. Contractile 7 
reprogramming was induced by either depletion of growth factors or addition of PD0325901, a 8 
clinically available MEK inhibitor. Next generation RNA-Sequencing was performed in naïve and 9 
differentiated human PCs to assess the whole-transcriptome profile. Three in vivo studies were 10 
conducted in C57BL6/J mice to determine: 1) the ability of human PCs to promote arteriole formation 11 
when implanted subcutaneously within PD0325901-containing Matrigel plugs, 2) the effect of orally 12 
administered PD0325901 on the arteriole density of normoperfused hearts, and 3) the possibility of  13 
promoting capillary formation and muscularization of the infarcted heart through the same 14 
pharmacological approach.  15 
Results: Removal of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) from 16 
the culture medium induced the differentiation of PCs into contractile VSMC-like cells. Because both 17 
growth factors induce the extracellular signal-regulated kinase 1/2 (ERK1/2) signalling, we attempted 18 
to induce PC differentiation in vitro and in vivo using PD0325901. RNA-sequencing revealed that 19 
differentiated PCs were enriched in transcripts associated with smooth muscle contraction and 20 
biological function. PD0325901-treated PCs rapidly acquired antigenic and functional features of 21 
contractile VSMCs in vitro. Moreover, human PCs formed new arterioles when implanted 22 
subcutaneously within PD0325901-containing Matrigel plugs in mice. Oral administration of 23 
PD0325901 for two weeks increased the density and expression of contractile proteins in small-calibre 24 
arterioles of the murine heart, thereby increasing myocardial perfusion. Similarly, PD0325901 induced 25 
reparative arteriologenesis and capillarization, reduced the scar, and improved left ventricular 26 
performance in a murine model of MI.   27 
Conclusion: We propose a novel method to promote the heart vascularization through the 28 
pharmacological modulation of resident mural cells. This novel approach could have an immediate 29 
impact on the treatment of coronary artery disease.  30 
 31 
 32 
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Clinical perspective 1 
What is new? 2 
 Human myocardial pericytes have intrinsic vascular plasticity that can be pharmacologically 3 
evoked using PD0325901, a clinically available MEK inhibitor.  4 
 In mice, the pharmacological inhibition of ERK1/2 signalling, by the oral administration of 5 
PD0325901 for 2 weeks, encouraged the heart arteriologenesis through pericyte differentiation. 6 
 In a preclinical mouse model of myocardial infarction, the oral administration of PD0325901 7 
for 2 weeks induced reparative arteriologenesis and capillarization, reduced the scar, and 8 
improved left ventricular performance. 9 
What are the clinical implications? 10 
 This novel drug-based therapeutic approach is readily available to all patients.  11 
 Therefore, it could have an immediate clinical impact for the treatment of coronary artery 12 
disease and other heart conditions associated with deficient coronary vascularization.  13 
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Non-standard abbreviations and acronyms 1 
ANGPT  angiopoietin 2 
ANOVA  analysis of variance 3 
ATP  adenosine triphosphate 4 
bFGF   basic fibroblast growth factor 5 
CAECs  coronary artery endothelial cells 6 
CALP   smooth muscle calponin  7 
cTn-I   cardiac troponin I 8 
DEGs   differentially expressed genes 9 
DMSO   dimethyl sulfoxide  10 
DPCs   PD0325901-differentiated PCs 11 
ECGM2 growth factor enriched pericyte medium 12 
ECM   extracellular matrix 13 
EGF   epidermal growth factor 14 
EGFR   EGF Receptor  15 
ELK1  E26 transformation-specific (ETS) Like-1 protein 16 
ERK1/2 extracellular signal-regulated kinase 1/2 17 
ET-1  endothelin-1 18 
FGFR  FGF Receptor 19 
GFs   growth factors 20 
GO  gene ontology 21 
HGF   hepatocyte growth factor 22 
LAD   left anterior descending 23 
LV   left ventricle 24 
LVEF   LV ejection fraction 25 
MEK1/2 dual specificity mitogen-activated protein kinase kinase 26 
MEKi  MEK inhibitor 27 
MI  myocardial infarction  28 
NG2  neuron-glial antigen 2 29 
NM-MyoIIB  non-muscle myosin IIB  30 
PCs  pericytes 31 
PDGF-BB  platelet-derived growth factor-BB  32 
PDGFRα platelet-derived growth factor receptor alpha 33 
PDGFRβ  platelet-derived growth factor receptor beta 34 
p-ERK1/2 phospho-ERK1/2 35 
PPI   protein-protein interaction 36 
SDF-1α stromal derived factor-1 alpha 37 
SM  smooth muscle 38 
SM22α  smooth muscle protein 22-alpha  39 
SMA-α  Smooth Muscle Actin-alpha 40 
SM-MHC  smooth muscle myosin heavy chain  41 
TCF21  transcription factor 21 42 
TUNEL  terminal deoxynucleotidyl transferase dUTP nick end labelling  43 
VEGF   vascular endothelial growth factor 44 
VSMCs  vascular smooth muscle cells  45 
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Introduction  1 
Cardiac repair after myocardial infarction (MI) results from a finely orchestrated series of 2 
events, including the appropriate and timely growth of pre-existent collateral arteries.1 Vascularization 3 
is also supported by angiogenesis, i.e. the formation of new capillaries, which eventually mature into 4 
new arterioles through the recruitment of mural cells.2 Patients capable of developing a good coronary 5 
circulation after an MI have a significantly reduced mortality risk compared with patients who have a 6 
poor coronary circulation.3 Therefore, there is a tremendous interest in deploying new therapies to 7 
reprogramming the vascularization potential of resident cardiac cells. 8 
Pericytes (PCs) are abundantly associated with capillaries and microvessels in the heart.4 They 9 
are considered mesodermal precursors, which share some antigenic markers with other stromal cells, 10 
such as myofibroblasts, but have distinct functional roles in vascular stabilization and remodeling.4-9 A 11 
lineage tracing study showed that epicardial PCs are the ancestors of coronary vascular smooth muscle 12 
cells (VSMCs) in the developing murine heart.10 Moreover, PCs participate in the “no-reflow” coronary 13 
vasoconstriction during post-ischemic reperfusion.11 Nonetheless, it remains unknown if cardiac PCs 14 
can be pharmacologically reprogrammed to acquire a contractile phenotype, thereby enhancing the 15 
muscularization of nascent arterioles in the infarcted heart.  16 
The present study aimed to determine the contribution of PCs to myocardial arteriologenesis. 17 
Results indicate that cultured cardiac PCs can switch to a VSMC-like phenotype following 18 
pharmacological inhibition of the extracellular signal-regulated kinase 1/2 (ERK1/2). The same 19 
pharmacological approach induced myocardial arteriologenesis in healthy and infarcted mice, which 20 
was combined with increased capillarization, reduced scars and improved ventricular performance in 21 
the latter. These findings open new therapeutic opportunities to treat coronary artery disease. 22 
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Methods  1 
Detailed procedures are described in the Supplemental material online. 2 
Ethics  3 
This study complies with the guidelines of the Declaration of Helsinki. Discarded material from 4 
congenital heart defect surgery was obtained with adult and paediatric patients' custodians' informed 5 
consent (ethical approval 15/LO/1064 from the North Somerset and South Bristol Research Ethics 6 
Committee). Donors and samples characteristics are described in Supplementary Table 1. 7 
Animals studies were covered by licenses from the British Home Office (30/3373 and PFF7D0506) and 8 
the University of Otago, New Zealand (AEC10/14), and complied with the EU Directive 2010/63/EU. 9 
Procedures were carried out according to the principles stated in the Guide for the Care and Use of 10 
Laboratory Animals (The Institute of Laboratory Animal Resources, 1996). Report of results is in line 11 
with the ARRIVE guidelines. 12 
Derivation of primary cultures of cardiac PCs 13 
Human and mouse PCs were immunosorted as CD31neg/CD34pos cells from human and mouse 14 
myocardial samples. Cells were expanded in full ECGM2 medium (PromoCell).   15 
In vitro studies 16 
Differentiation of PCs and coronary artery VSMCs (CASMCs) employed either growth factors (GFs) 17 
depletion or PD0325901 (250 nM) treatment. Functional in vitro assays included antigenic profile (by 18 
real-time qPCR, immunocytochemistry and western blotting), contraction (embedding of cells in 19 
collagen gels), migration (wound healing), angiogenesis (2D-matrigel), calcium flux (Fluo-4 dye-based 20 
visualisation of calcium) and production of extracellular matrix (ECM). When required, cells were 21 
stimulated with the vasoconstrictor Endothelin-1 (ET-1). Antibodies for immunofluorescence in tissues 22 
and cells, and western blotting are reported in Supplementary Tables 2&3. Primers are listed in 23 
Supplementary Table 4.  24 
Next-generation RNA-Sequencing 25 
Strand-specific RNA-sequencing was carried out on total RNA in naïve and PD0325901-differentiated 26 
PCs, and CASMCs as control, using an Illumina HiSeq platform, with a 2x150bp configuration, ~20M 27 
reads per sample. 28 
In vivo studies 29 
Three randomized, controlled experiments were conducted in mice.  30 
Study 1: Male C57BL6/J mice (n=4/group) were injected subcutaneously, on both flanks, with Matrigel 31 
plugs containing human PCs and either PD0325901 (500 nM) or vehicle, and sacrificed seven days later 32 
for histological study of PC plasticity.  33 
Study 2: Female C57BL6/J mice received either PD0325901 (orally, 10 mg/kg/day) or vehicle for 34 
fourteen days (n=11/group). Endpoints were myocardial perfusion (assessed using fluorescent 35 
microspheres), left ventricular (LV) performance (echocardiography), and vascularization 36 
(immunohistochemistry). 37 
Study 3: Female C57BL6/J mice underwent permanent ligation of the left anterior descending (LAD) 38 
coronary artery, followed by oral administration of PD0325901 (orally, 10 mg/kg/day) or vehicle for 39 
fourteen days (n=12/group). Endpoints included LV performance, vascularization, and scar size.  40 
Statistics 41 
Data were analyzed using Prism version 6.0 or 8.0 and expressed as means ± standard error of the mean 42 
or standard deviation. Statistical differences were determined using T-tests and ANOVAs, unless 43 
otherwise stated. Analyses of in vivo outcomes followed the intention-to-treat principle.  44 
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Results  1 
Human cardiac PC characterization 2 
As previously reported in neonatal hearts,12 CD31neg alpha-Smooth Muscle Actin (αSMA)neg 3 
CD34pos Platelet-Derived Growth Factor Receptor Beta (PDGFRβ)pos PCs were identified around 4 
capillaries and within the adventitia of arteries in adult human hearts using immunofluorescence 5 
microscopy (Figure 1A-C). CD31neg CD34pos sorted PCs grew in culture, either as a bulk population or 6 
single cell-derived clones, showing a spindle-shaped morphology and typical antigenic profile (Figure 7 
1D&E and Supplementary Figure 1).12 Compared with cardiac fibroblasts, PCs express remarkably 8 
lower levels of PDGFRα (<10% of positive cells, Figure 1E) and transcription factor 21 (TCF21) 9 
(Figure 1F&G), thus confirming the difference between the two populations.13-15 Cardiac PCs secrete 10 
angiogenic factors Hepatocyte Growth Factor (HGF), Angiopoietin (ANGPT)-1 and -2 and Vascular 11 
Endothelial Growth Factor (VEGF) (Figure 1H), and promote the formation and stabilization of 12 
coronary artery EC (CAEC) networks in Matrigel assays in vitro through physical interaction with ECs 13 
(Figure 1I). Controls for the above experiments are supplied in Supplementary Figure 2. 14 
 15 
EGF and bFGF restrain cardiac PCs from differentiation into VSMC-like cells  16 
PCs retained their original phenotype during culture expansion in GF-enriched medium 17 
(ECGM2) (All GFs, Figure 2). Using immunocytochemistry (Figure 2A), qPCR (Figure 2B) and 18 
western blotting (Figure 2C), we showed that GF depletion for ten days induced PCs to acquire 19 
intermediate and late-stage contractile proteins (No GFs). Supplementation of epidermal growth factor 20 
(EGF) and basic fibroblast growth factor (bFGF), alone and even more in combination, to basal 21 
medium, prevented the expression of smooth muscle (SM)-specific markers (+EGF/bFGF, Figure 2 22 
and Supplementary Figure 3). Conversely, the presence of VEGF and insulin-like growth factor 1 23 
(IGF1) alone or together, in the absence of EGF and bFGF, induced SM-markers (-EGF/bFGF, Figure 24 
2 and Supplementary Figure 4). VSMC markers used for these analyses were smooth muscle myosin 25 
heavy chain (SM-MHC, gene MYH11), non-muscle myosin IIB (NM-MyoIIB, MYH10), Smoothelin B 26 
(SMTN), SM-Calponin (CALP, CNN1), SM alpha-actin (αSMA, ACTA2), and Smooth Muscle Protein 27 
22-Alpha (SM22α, TAGLN) (described in Supplementary Table 5). Both PCs and PC-derived VSMC-28 
like cells retained the expression of Neuron-Glial antigen 2 (NG2 - CSPG4) and PDGFRβ (PDGFRB), 29 
antigens shared by PCs and VSMCs (Supplementary Figure 5). We confirmed the GF-modulated 30 
plasticity in single PC-derived clones (Supplementary Figure 6). 31 
Human CASMCs were also responsive to GF depletion, acquiring the contractile marker SM-32 
MHC along with upregulation of other SM-markers (Supplementary Figure 7).  33 
 34 
GF-depleted PCs display functional properties of contractile VSMCs 35 
We next assessed key functional characteristics of PCs differentiated through GF depletion, 36 
namely contraction, calcium flux, migratory ability, and production of ECM (Figure 3). When 37 
embedded into collagen gels, differentiated PCs, but not naïve PCs, contracted in response to 38 
vasoconstrictor ET-1, this response being prevented by butanedione monoxime, a myosin ATPase 39 
inhibitor (Figure 3A). Endothelin-induced contraction is calcium-dependent; a Fluo-4 calcium flux 40 
assay showed that differentiated PCs were characterized by a greater and faster intracellular calcium 41 
mobilization in response to ET-1 compared with naïve PCs (Figure 3B). Differentiated PCs did not 42 
migrate in response to Platelet-Derived Growth Factor-BB (PDGF-BB), Stromal Derived Factor-1 43 
alpha (SDF-1α) or VEGF-A, whereas naïve PCs did so (Figure 3C). Moreover, differentiated PCs 44 
produced lower amounts of fibronectin (FN1) but more elastin (ELN) (Figure 3D). 45 
Like differentiated PCs, differentiated contractile CASMCs showed limited ability to migrate 46 
and secreted elastin (Supplementary Figure 8).  47 
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Together, these results indicate that GF-depleted PCs acquire not only antigenic but also typical 1 
functional features of contractile VSMCs.  2 
 3 
ERK1/2 signalling controls the PC switch to VSMC-like cells in vitro  4 
We next analysed the signalling activated by EGF and bFGF in cardiac PCs. A phospho-kinase 5 
array screening of PCs cultured in the presence or absence of GFs showed that only EGF and bFGF 6 
activate ERK1/2 and its downstream targets (Supplementary Figure 9A). Western blotting confirmed 7 
the phosphorylation-activation of the EGF Receptor (EGFR)-FGFR-ERK1/2-ELK1 axis 8 
(Supplementary Figure 9B). Phosphorylation-activation of ELK1 (E26 transformation-specific (ETS) 9 
Like-1 protein) by ERK1/2 reportedly prevents SM genes transcription.16, 17 In view of a clinical 10 
application, we adopted a pharmacologic inhibitory approach based on the use of small bioactive 11 
molecules to investigate the role of this signalling in controlling PC differentiation. A pilot screening 12 
of four candidates (Genistein, EGFR and FGFR inhibitor; U0126, PD98059 and PD0325901, dual 13 
specificity mitogen-activated protein kinase kinase (MEK)1/2 inhibitors (MEKi)), identified 14 
PD0325901 as the most potent inhibitor of MEK activity in cardiac PCs (data not shown). PD0325901 15 
binds to an allosteric site in the MEK1/2 activation loop in an Adenosine Triphosphate (ATP)-non-16 
competitive fashion, thereby preventing its activation and kinase activity. 17 
Dose-response studies demonstrated that PD0325901, used at 250-500 nM, prevents ERK1/2 18 
phosphorylation for at least 48 hrs without affecting PC viability when assessed up to 10 continuous 19 
days of culture (Supplementary Figure 10).  20 
 21 
Next-generation RNA-sequencing shows that differentiated PCs are enriched with contractile 22 
mRNA transcripts  23 
We next performed a whole-transcriptome analysis of naïve and PD0325901-differentiated PCs 24 
(DPCs) to establish if the pharmacological treatment could shift the global cell transcriptome towards 25 
the VSMC lineage. CASMCs were used as the internal control. As shown in Figure 4A, the 26 
bioinformatic analysis indicated that a cluster of genes was upregulated in both DPCs and CASMCs as 27 
compared with naïve PCs. Zooming into this cluster unveiled several gene transcripts associated with 28 
SM contraction and differentiation (Figure 4B). Moreover, the number of genes co-expressed by DPCs 29 
and CASMCs was 3-fold higher than that shared by naïve PCs and CASMCs (Figure 4C).  30 
The contrast between DPCs vs PCs revealed 1,870 differentially expressed genes (DEGs, false 31 
discovery rate < 0.05 and absolute log2 fold change > 1), of which 1,037 upregulated and 833 32 
downregulated (Figure 4D). The KEGG pathway Vascular smooth muscle contraction evidenced 33 
several genes upregulated in DPCs (Figure 4E&F, min log2 fold change +1.8, max +12.7). These genes 34 
were further analyzed in a STRING network, which showed that 13 proteins encoded by those genes 35 
have a strong biological connection (high confidence interaction score of 0.7 and protein-protein 36 
interaction (PPI) enrichment p-value < 1e-16)  (Figure 4G). Among the main biological processes 37 
emerging from this analysis, there is Vascular smooth muscle contraction (MYH11, log2 fold change = 38 
+12.7; ACTA2, +4.5; endothelin A/B receptors, EDNRA/B, both +3.7; SM Myosin light chain kinase, 39 
MYLK, +3.4) and Actomyosin structure organization (MYH11; CNN1, +4.4; Leiomodin 1, LMOD1, 40 
+4.4). Actomyosin is the molecular complex deriving by the association of actin and myosin, which 41 
ensures muscle cell contraction. The Endothelin receptor signalling is also instrumental in VSMC 42 
contraction. Besides, some hits of the network are involved in the control of the calcium flux and related 43 
to the Regulation of muscle contraction (Calcium channel, voltage-dependent, L type, alpha 1C, 44 
CNCNA1C, log2 fold change +5; Protein phosphatase 1 regulatory subunit 12B, PPP1R12B, +2.7). 45 
Other emerging processes are Blood vessel development, Actin filament-based process and 46 
Vasodilation, all related to blood vessels formation and function. As expected, the whole-genome 47 
contrast between DPCs vs PCs showed that the biological processes Cytokine-cytokine receptor 48 
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interaction and MAPK signalling were downregulated in DPCs (Figure 4H). A schematic view of the 1 
two main regulated pathways is further illustrated in Supplementary Figure 12. Again, DPCs showed 2 
an upregulation of biological processes involving the cytoskeleton and actin filament organization 3 
(Figure 4H). Conversely, pathways controlling cell motility and migration were downregulated 4 
(Figure 4H). 5 
We also analyzed how the expression of classical pericyte-associated transcripts changed in 6 
cardiac PCs after the MEKi treatment (Figure 4I). Five of these genes, reportedly shared by PCs and 7 
VSMCs, were upregulated in DPCs (Angiotensinogen, AGT, log2 fold change +10.4; Desmin, DES, 8 
+9.4; Regulator of G-protein signalling 5, RGS5, +7.5; CSPG4, +4.6; and PDGFRB, +1.4). As 9 
expected, three transcripts recently associated with pericytes but not VSMCs of the adult human heart,7 10 
were downregulated in DPCs (Potassium inwardly-rectifying channel, KCNJ8, -1.1; ATP-binding 11 
cassette, sub-family C member 9, ABCC9, -1.3; Neural Cell Adhesion Molecule 2, NCAM2, -2.4).  12 
Last, we performed an analysis of angiogenesis-related genes. As shown in (Figure 4J), 22 13 
genes were differentially expressed between DPCs and PCs (cut-off absolute log2 fold change > 1.5). 14 
A STRING network analysis of the encoded proteins showed 15 genes are biologically connected with 15 
a confidence interaction score of 0.7 and PPI enrichment p-value < 1e-16 (Figure 4K). Among the most 16 
downregulated genes, there are ANGPT2 (encoding ANGPT-2, log2 fold change -4.89) and TIE1 17 
(Tyrosine-Protein Kinase Receptor Tie-1, -4.33), whose proteins are associated with vascular 18 
regression, and SERPINF1 (Serpin Family F Member 1, -3.42), a potent secreted inhibitor of 19 
angiogenesis. Among the most upregulated genes, we find two factors which are known to be secreted 20 
by PCs: LEP (Leptin, +7.55) and PDGFB (Platelet-Derived Growth Factor Subunit B, +3.13). Both 21 
factors induce EC proliferation. Moreover, the first protein was previously associated with a positive 22 
pro-angiogenic outcome of PCs, while the latter plays an essential role in mural cells survival and blood 23 
vessel development. Finally, eight genes are involved in the extracellular matrix organization, a process 24 
required to support the remodelling of the microvasculature.  25 
Altogether, these findings indicate that, while retaining a transcriptional distinction from 26 
VSMCs, DPCs are characterized by the expression of a cluster of gene transcripts instrumental to 27 
contractile function and stationary behaviour. At the same time, cells downregulate typical pericyte 28 
transcripts and acquire a pro-angiogenic profile. 29 
 30 
PD0325901 induces the differentiation of cardiac PCs into functional VSMC-like cells in vitro 31 
The next step was to validate the phenotypical and functional properties of DPCs. The analysis 32 
of mRNA transcripts in PD0325901-treated PCs confirmed the upregulation of the contractile VSMC 33 
genes MYH11, ACTA2, CNN1 and TAGLN (Supplementary Figure 12A). Furthermore, PD0325901-34 
treated cells retained the expression of the common pericyte/VSMC antigens NG2 (CSPG4) and 35 
PDGFRβ (PDGFRB) (Supplementary Figure 12B&C), while showing downregulation of FN1 and 36 
upregulation of ELN genes compared with naïve PCs (Supplementary Figure 12D). 37 
As shown in Figure 5A-D, the addition of PD0325901 to the GF-supplemented medium 38 
induced cardiac PCs to acquire the expression of contractile proteins that characterize the VSMC-like 39 
phenotype of GF-depleted PCs. In the absence of GFs, PD0325901 further enhanced the expression of 40 
SM-MHC, a specific marker of contractile VSMCs, compared with vehicle (Figure 5C, western 41 
blotting analysis). Intriguingly, PD0325901 was faster than GF depletion in inducing the expression of 42 
CALP, αSMA and SM22α (Supplementary Figure 13).  43 
PCs differentiated with PD0325901 in the presence of all GFs contracted in response to ET-1 44 
(Figure 5E), became unresponsive to pro-migratory stimuli (Figure 5F), and showed reduced 45 
proliferation, which are properties of contractile VSMCs (Supplementary Figure 14). Conversely, the 46 
cell cycle inhibitor hydroxyurea was unable to induce PC differentiation (Supplementary Figure 15).  47 
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PD0325901 upregulated contractile markers and inhibited proliferation also in control 1 
CASMCs (Supplementary Figure 16).  2 
Interestingly, DPCs also showed a superior capacity to support angiogenesis in co-cultures with 3 
CAECs (Figure 5G), and gained the ability to assemble in tubular networks when seeded on the top of 4 
Matrigel (Figure 5H).  5 
These findings indicate that ERK1/2 is a master controller of PC differentiation and that its 6 
inhibition can encourage both PCs and CASMCs towards a contractile phenotype. 7 
 8 
Human cardiac PCs differentiate into VSMC-like cells upon transplantation in vivo 9 
We next investigated the potential of cardiac PCs to generate VSMC-like cells in vivo. Cardiac 10 
PCs were embedded in Matrigel containing either PD0325901 or vehicle and injected subcutaneously 11 
in C57BL6/J mice (Figure 6A). Plugs were harvested after seven days, and an antibody against the 12 
human Ku80-XRCC5 antigen was employed to recognize transplanted PCs (Supplementary Figure 13 
17A). Matrigel was revealed using a secondary antibody anti-mouse (Supplementary Figure 17B). A 14 
small fraction of spindle-shaped PCs within the Matrigel stained positive for αSMA and CALP in the 15 
vehicle group (18.0% and 3.7% of total cells, respectively) these numbers being increased by 16 
PD0325901 (45% and 23% of total cells, respectively) (Figure 6B&C). Moreover, in the PD0325901 17 
group, we could identify occasional SM-MHC-positive cells (Figure 6D). Intriguingly, the three-18 
dimension (3D) reconstructions of 15 μm-thick Matrigel sections evidenced the presence of tubular-19 
like structures only in PD0325901 plugs (Figure 6E). Immunohistochemistry quantification of CD45pos 20 
cells documented a similar influx of immune/inflammatory cells within the vehicle- and PD0325901-21 
plugs, ruling out host immune response was relevant for differences regarding implanted cells between 22 
the two groups (Supplementary Figure 17C).  23 
 24 
PD0325901 promotes myocardial arteriologenesis in healthy mice 25 
We detected CD31neg αSMA/CALPneg CD34pos PDGFRβpos cells around arterioles and 26 
capillaries in the mouse heart (Supplementary Figure 18A&B) and confirmed that in vitro cultures of 27 
murine PCs have a phenotype like the human PCs (Supplementary Figure 18C&D). Treatment of 28 
murine PCs with 250 nM PD0325901 increased the expression of contractile SM-proteins while halting 29 
cell proliferation (Supplementary Figure 18E-G). 30 
A controlled, randomized study was then conducted in C57BL6/J mice receiving PD0325901 31 
at 10 mg/kg/day or vehicle (dimethylsulfoxide -  DMSO), orally for 14 days (Figure 7A). Baseline and 32 
endpoint indexes of LV function and dimension were similar between the experimental groups, as 33 
assessed by echocardiography (Supplementary Table 6). The inhibition of MEK1/2 activity in 34 
PD0325901-treated mice was confirmed by the absence of immunostaining for p-ERK1/2 in the heart 35 
(Supplementary Figure 19A) and by western blotting analysis of p-ERK1/2 in the liver 36 
(Supplementary Figure 19B). Moreover, safety was confirmed by verifying the treatment did not 37 
cause apoptosis in cardiomyocytes, vascular cells, and interstitial cells (terminal deoxynucleotidyl 38 
transferase dUTP nick end labelling - TUNEL assay) (Supplementary Figure 19C) or increase in 39 
plasmatic levels of cardiac troponin I (cTn-I) (Supplementary Figure 19D).  40 
Histological analyses showed the density of arterioles was increased in the LV of PD0325901-41 
treated mice compared with the vehicle group (Figure 7B&C), whereas cardiomyocyte cross-sectional 42 
area (CSA) and density were similar between the two groups (Supplementary Figure 19E&F). 43 
Interestingly, although the increase in vascular density could be attributed to small arterioles only 44 
(Figure 7D), the relative expression of mature vs. early contractile proteins in VSMCs of the vascular 45 
wall, was augmented by PD0325901 in the whole spectrum of arterioles (Figure 7E&F). Moreover, 46 
PD0325901 reduced the percentage of small arterioles covered with a CD34pos layer (53% vs. 70% of 47 
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total arterioles in the vehicle) (Figure 7G&H) as well as the ratio between the area occupied 1 
respectively by perivascular CD34pos cells and αSMApos VSMCs (Figure 7G&I).  2 
Venous vessels were recognized with the capillary- and vein-endothelium specific antigen 3 
Endomucin and excluded from the analysis (Supplementary Figure 19G). The PD0325901 treatment 4 
did not affect capillary density (Supplementary Figure 19H).  5 
The observed structural changes were translated into an improvement of myocardial perfusion 6 
in the PD0325901 group (6.8 vs. 5.3 ml/min/g of LV tissue in vehicle) (Figure 7J).  7 
 8 
PD0325901 improves LV function and revascularization in a mouse MI model 9 
  Finally, a controlled, randomized study was conducted in C57BL6/J mice with MI. Three-days 10 
post-MI, mice were given PD0325901 at 10 mg/kg/day or vehicle (DMSO), orally for 14 days (Figure 11 
8A). Echocardiography confirmed the proper induction of MI. Baseline indexes of LV function did not 12 
differ between groups.  13 
At the endpoint, PD0325901-treated mice showed reduced LV dilatation (Supplementary 14 
Table 7) and improved contractile function, as indicated by higher LV ejection fraction (LVEF, +11.4 15 
percent points vs. vehicle), stroke volume (+52% vs. vehicle), and cardiac output (+56% vs. vehicle) 16 
(Figure 8B-D). Survival rate did not differ between groups (Figure 8E). However, the composite 17 
endpoint of survival and LVEF above 30% was significantly better in the PD0325901 group (Fisher 18 
exact test: p=0.0272) with an improved relative risk of 2.20 (95% CI = 1.23 to 4.80). 19 
 Histological examination evidenced that mice in the PD0325901-group had a smaller infarct 20 
size (38 vs. 48% of the LV in controls) (Figure 8F). Moreover, in the peri-infarct zone, PD0325901 21 
induced a significant increase in the density of small (69 vs. 45 art/mm2 in controls) and large arterioles 22 
(26 vs. 19 art/mm2 in controls) (Figure 8G&H). Similarly, capillary density was higher in the 23 
PD0325901 group (5,700 vs. 4,700 cap/mm2 in controls) (Figure 8G&I). Conversely, PD0325901 did 24 
not modify vascularization in the remote myocardium (Figure 8J&K).   25 
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Discussion  1 
Here, we provide a new mechanistic understanding of cardiac PC potential in vascular 2 
remodelling. In the heart, PCs may represent an incremental cellular reservoir for fuelling 3 
arteriologenesis in conditions of ischemic injury. Importantly, we show that myocardial vascularization 4 
can be pharmacologically modulated in vivo using the selective MEK inhibitor PD0325901, although 5 
differences were observed between the normoperfused and ischemic murine heart. In the former, 6 
PD0325901 administration induced a generalized increase in small arterioles without affecting capillary 7 
density, whereas, when started at the early recovery stage from acute non-reperfused MI, the inhibitor 8 
potentiated both small and large arterioles selectively within the peri-infarct zone and also incited 9 
capillarization. Thus, the approach could have incremental therapeutic activities in specific areas of the 10 
heart depending on the underlying state of the coronary circulation and the occurrence of regional 11 
ischemia. Although additional investigation is needed, our findings raise the intriguing possibility of 12 
manipulating mural cells to generate a robust microvasculature in the adult heart.  13 
We observed that DPCs became able to assemble in vascular-like tubes in an in vitro 14 
angiogenesis assay, along with forming more complex tubular networks in cooperation with ECs. 15 
Transcriptomic analysis further showed that DPCs acquired a pro-angiogenic profile whose most 16 
relevant elements are the downregulation of potent disruptors of angiogenesis, namely ANGPT2, TIE1 17 
and SERPINF1, paralleled by the induction of pro-angiogenic factors LEP and PDGFB. ANGPT2 18 
antagonizes the pro-angiogenic ANGPT1/Tie2 signalling and was reported to be upregulated in the 19 
ischemic heart in mice and to cause abnormal vascular remodelling.18 Leptin is reportedly expressed by 20 
perivascular PDGFRβpos cells,19 and contributes to the pro-angiogenic activity of transplanted PCs in a 21 
mouse model of limb ischemia.20 Potentiation of angiogenesis and arteriologenesis is crucial in 22 
preserving  cardiomyocyte viability in the area at risk, which may account for the finding of a smaller 23 
infarct scar documented in the PD0325901-treated group at sacrifice, 2 week after MI induction. 24 
We discovered that EGF and bFGF play a primary role in the preservation of proliferative, 25 
undifferentiated cultures of cardiac PCs, through the activation of the ERK1/2 signalling. In contrast, 26 
upon GF depletion, PCs undertake a phenotypic switch to VSMCs. In vitro, differentiated PCs become 27 
stationary in migration assays, express elastin and contractile fibres typical of VSMCs, and also gain 28 
functional contractile features, as shown by the calcium inflow and ability to contract following ET-1 29 
stimulation. It is known that bFGF inhibits transforming growth factor-beta 1 (TGFβ1)-driven 30 
activation of SM contractile gene expression in PCs and VSMCs.21-23 However, this is the first 31 
demonstration that cardiac PCs are intrinsically committed to a SM phenotypic switch upon removal of 32 
the inhibitory GFs. Both EGF and bFGF are upregulated in the acutely infarcted heart and unpublished 33 
data confirmed the elevation of the two GFs in peripheral blood of patients with recent MI (Katare et 34 
al, 2020). It is therefore plausible that PCs are initially restrained from differentiation into VSMC-like 35 
cells following an acute myocardial injury, participating in arteriologenesis upon GF downregulation 36 
during later recovery stages. A pharmacological approach impacting on the EGF-bFGF-ERK1/2 37 
signalling could be a viable means to promote prompter arteriologenesis of the heart. 38 
Several lines of evidence support this possibility. Administration of PD0325901, a targeted 39 
MEK1/2 inhibitor, evoked a SM phenotypic switch in human cardiac PCs cultured in the presence of 40 
GFs. This change was validated using RNA-Seq, which showed an upregulation of several clusters of 41 
genes associated with SM contraction and function in DPCs. Despite the whole transcriptome profiling 42 
indicated that DPCs were different from CASMCs, the upregulation of SM pathways in PCs was crucial 43 
to confer the cells with both phenotypic and functional properties of contractile VSMCs, as 44 
demonstrated by in vitro studies. We cannot exclude that this transformation is further magnified in 45 
vivo. We also observed that the MEKi induced the expression of mature contractile VSMC markers in 46 
proliferating CASMCs in vitro. These data support the intriguing possibility that different mural cell 47 
types can participate in muscular remodelling of the myocardial vasculature. PD0325901 was 48 
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previously used to induce the complete differentiation of immature SMCs derived from human 1 
pluripotent stem cells.24 Interestingly, in our system, the effect of PD0325901 was faster and more 2 
potent than that observed by withdrawing GFs from the culture environment. Moreover, we have 3 
demonstrated the pro-arteriologenesis effect of PD0325901 in vivo using Matrigel plug-implanted PCs. 4 
In this assay, the acquisition of the late-stage differentiation marker SM-MHC was low, possibly 5 
because of the dispersion of the MEKi in the surrounding tissues. Therefore, we designed new 6 
experiments using daily, oral administration of the drug, to verify cardiac safety and efficacy in 7 
normoperfused and ischemic murine hearts. In both models, we confirmed that the treatment promotes 8 
myocardial vascularization. The increase in arteriologenesis might be attributed, at least in part, to the 9 
differentiation of PC-covered vascular structures into mature αSMApos arterioles. Additionally, 10 
angiogenic capillaries in the infarct border zone could be muscularized through the recruitment and 11 
differentiation of synthetic VSMCs and PCs. The contribution of cell proliferation cannot be excluded, 12 
although GF depletion and ERK1/2 inhibition exerted anti-proliferative activity on PCs. 13 
Clinical relevance and study limitations  14 
This study documents that myocardial PCs are endowed with intrinsic vascular plasticity, which 15 
can be pharmacologically reprogrammed to encourage arteriologenesis and angiogenesis. Short-16 
duration treatment with PD0325901 may aid the recovery from MI through enhanced vascularization 17 
of the area at risk. It is also worth to report that PD0325901 showed efficacy in reducing neointima 18 
formation in a mouse model of arterial stenosis,25 which increases the potential cardiac benefits of this 19 
class of compounds. Additional studies are warranted to demonstrate the benefit of repeated MEKi 20 
administration in ischemic heart failure and diseases characterized by arteriole regression, such as 21 
diabetic cardiomyopathy. In this respect, chronic treatment may require lowering the therapeutic dosage 22 
to avoid cardiotoxicity.26, 27 This was not a case in our study, where a short-duration treatment with a 23 
specific MEK1/2 inhibitor was applied.  24 
Last, although this study focused on the analysis of vascular mural cells, we are fully aware 25 
that the direct beneficial effect of the MEKi on other cardiac cell types cannot be excluded and merits 26 
further investigation. This does not diminish the translational significance of presented findings, rather 27 
strengthens the concept that the heart has an intrinsic reparative potential worth to be aided after an 28 
acute ischemic injury.  29 
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Figure 1. Human cardiac PC characterization. (A-C) Confocal immunofluorescence images of 
human hearts. Arrows point to CD31neg αSMAneg CD34pos PDGFRβpos PCs around capillaries (A) and 
arterioles (B&C). C: capillary. (D) Brightfield microphotograph of expanded PCs. (E) 
Immunofluorescence images and bar graphs showing PC antigenic profile at passage 5 of culture. N=4. 
(F&G) Expression of TCF21 in cardiac PCs and fibroblasts evaluated by RT-qPCR (F) and western 
blot (G). N=3 fibroblasts and N=5 PCs. (H) Pro-angiogenic factors secreted by cardiac PCs. N=4. (I) 
2D-Matrigel assay with human coronary artery ECs (CAEC) alone or in co-culture with cardiac PCs. 
PCs were labelled with dil (red fluorescence). Black arrows point to examples of PCs. N=5. All values 
are means ± SEM. * P<0.05, ** P<0.01. 
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Figure 2. EGF and bFGF control the VSMC potential of human cardiac PCs. (A) 
Immunofluorescence images showing expression of VSMC markers by naïve and differentiated PCs 
when cultured with different combinations of GFs for ten days. All GFs: VEGF, IGF-1, EGF, bFGF. 
No GFs: depletion of all GFs. - EGF/bFGF: only VEGF and IGF1. + EGF/bFGF: only EGF and 
bFGF. (B) Transcriptional analysis of SM-genes. mRNA data are expressed as fold change of CASMCs 
used as reference (dashed line at y=1). (C) Western blotting analysis of VSMC markers. Blots show a 
representative PC line. Graphs report blots densitometry. N=5. Values are means ± SEM. * P<0.05, ** 
P<0.01, *** P<0.001, **** P<0.0001.  
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Figure 3. Functional assays confirm that differentiated human cardiac PCs gain properties of 
contractile VSMCs. Assays were performed at the end of a 10-day culture with or without GFs. (A) 
Contraction assay. Cells were embedded in collagen gels, treated with a contraction inhibitor and 
stimulated with Endothelin-1 (ET1). Bar graphs indicate the % of gel contraction after 24h. N=4. (B) 
Fluo-4 calcium assay. The Fluo-4 dye was loaded into the cells and these were stimulated with ET1 or 
vehicle. Images were recorded every 20 sec for 10 min. The intracellular calcium flux was measured as 
relative fluorescence units (RFU - green fluorescence of Fluo-4). N=2. The curves show 1 PC line. (C) 
Gap closure migration assay. Migration time was 24h. Absence of stimuli was the control - CTRL. 
Cells were stained for DAPI and αSMA at the end of the experiment. Bar graphs show the area of the 
final gap. N=3. (D) Expression of extracellular matrix (ECM) markers. Blots and bar graphs show 
the expression of ECM proteins and relative genes. Blots are representative of one PC line. mRNA data 
are expressed as fold change of CASMCs used as reference (dashed line at y=1). N=5. All values are 
means ± SEM. * P<0.05, ** P<0.01, *** P<0.001. 
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Figure 4. Next-generation RNA-sequencing analysis of naïve and differentiated human cardiac 
PCs. (A) K-means KEGG analysis of differentially expressed genes (DEGs) in PC, drug-differentiated 
PC (DPC) and CASMCs. (B) List of most predominant genes associated with the pathway Vascular 
smooth muscle contraction. (C) Venn diagram showing the number of genes expressed uniquely or 
shared by the three populations of cells. (D-G) Comparison of contractile VSCM-related genes in DPC 
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vs naïve PC. (D) MA-plot representing genes differentially expressed by the two populations of cells. 
(E) List of most regulated KEGG pathways. (F) DEGs associated with Vascular smooth muscle 
contraction. (G) STRING protein-protein interaction analysis of genes in (F), and emerging gene 
ontology (GO) terms: Biological Process. (H) Main pathways resulting from the GO Biological Process 
analysis of DPC vs PC. (I) Differential analysis of pericyte related transcripts in DPC vs PC. (J) 
Analysis of angiogenesis-related DEGs in DPC vs PC. Genes were selected according to absolute log2 
fold change > 1.5. (K) STRING network analysis of angiogenesis-related genes and emerging GO 
terms: Biological Process. In A, B, D, E, F, H, I and J, events upregulated are shown in red, 
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Figure 5. Inhibition of the MEK1/2 - ERK1/2 signalling induces the differentiation of human 
cardiac PCs into VSMC-like cells. (A) Schematic showing EGF and bFGF signalling. We have 
employed the MEK1/2 inhibitor PD0325901 to prevent ERK1/2 activation in PCs. Before using the 
cells for the functional assays, PCs were cultured for ten days with different media as indicated, and in 
the presence of PD0325901 (PD - 250 nM) or DMSO (Veh). (B-C) Protein expression analyses using 
western blotting. Representative blots from one patient and graphs reporting blots densitometry. N=5. 
(D) Immunofluorescence images showing expression of VSMC markers. (E) Contraction assay. Cells 
were embedded in collagen gels, treated with a contraction inhibitor and stimulated with Endothelin-1 
(ET1). Bar graphs indicate the % of gel contraction after 24h. N=4. (F) Gap closure migration assay. 
Migration time was 24h. Green fluorescence indicates Calponin, in blue DAPI. Bar graphs show the 
area of the final gap. N=4. (G) 2D-Matrigel assay with human coronary artery ECs (CAEC) and 
PCs. CAECs were used alone as control, or in co-cultures with cardiac PCs. N=3 to 5. (H) 2D-Matrigel 
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assay with PCs. PCs alone were seeded on the top of Matrigel. N=6. In (G&H) bar graphs indicate the 
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Figure 6. Human cardiac PCs differentiate into VSMC-like cells upon transplantation in vivo. (A) 
Experimental protocol of the Matrigel plug assay. (B-D) Immunofluorescence images of Vehicle (Veh) 
and PD0325901 (PD) Matrigel plugs showing that human cells express VSMC markers. Bar graphs 
report the percentage of human cells expressing α-SMA and Calponin. N=7-8/group. Values are means 
± SEM. ***P<0.001. (E) Immunofluorescence images documenting the presence of α-SMApos vascular-
like structures within the PD0325901-plugs.  
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Figure 7. A 2-week treatment with PD0325901 promotes arteriologenesis and increased perfusion 
of the healthy mouse heart. (A) Experimental design. (B-D) Analysis of arteriole density. (B) 
Confocal immunofluorescence image of the LV showing examples of arterioles expressing αSMA but 
negative for Endomucin (marker of vein and capillary endothelium). Graphs showing the density of 
total arterioles (C) and arterioles categorized according to their lumen size (D).  Data are expressed as 
the number of arterioles per mm2. (E&F) Analysis of arteriole maturation. (E) Confocal 
immunofluorescence image showing arterioles expressing αSMA and SM-MHC. (F) Graph reporting 
arterial VSMC maturation evaluated as the ratio between the areas occupied by SM-MHC and αSMA. 
(G-I) Analysis of perivascular CD34+ cells. (G) Confocal immunofluorescence image showing αSMA+ 
arterioles surrounded by adventitial CD34+ cells. (H) Graphs reporting arterioles surrounded by CD34+ 
cells expressed as a percentage of total arterioles. (I) Coverage of arterioles with CD34+ cells was 
evaluated as the ratio between the areas occupied by CD34 and αSMA. In (C-I) N=5/group. (J) Left 
ventricle blood flow. N=6 Veh, N=5 PD. For all graphs, individual values and means ± SEM. *p<0.05. 
Veh: vehicle. PD: PD0325901. Art: arteriole. 
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Figure 8. A 2-week treatment with PD0325901 improves LV function and vascularisation in a 
mouse MI model. (A) Experimental design. (B-D) Graphs showing basal and final echocardiography 
indexes. For Vehicle: N=12 basal, N=8 final; PD: N=12 basal, N=11 final. Individual values and means 
± SD. (E) Graph reporting mice survival. (F) Representative images showing the Azan-Mallory staining 
of the LV and bar graphs indicating the quantification of the infarct size. N=8 Veh, N=10 PD. (G) 
Representative immunofluorescence images showing arterioles (αSMA, red fluorescence) and 
capillaries (Isolectin B4, green) in the peri-infarct myocardium of mice receiving vehicle or treatment. 
The dashed line defines the infarct zone (IZ). (H-K) Graphs reporting the quantification of arteriole and 
capillary density in the peri-infarct and remote LV myocardium of mice receiving vehicle or treatment. 
N=7 per group. In (F-K), individual values and means ± SEM. For all graphs, *p<0.05, **p<0.01, 
***p<0.001 as indicated. Veh: vehicle. PD: PD0325901. 
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Supplementary Figure 1. Human cardiac PCs are a clonogenic population. (A) Cartoon
showing the experimental protocol for the single cell cloning. (B) Table summarising the results
of the cloning assay with N=3 PCs. (C) Brightfield microphotograph of an expanded clone of
PCs at passage 5 showing the characteristic spindle shape. (D) Representative
immunofluorescence images showing the antigenic profile of a clone of PCs at passage 5 of
culture. N=4 clones assayed, all belonging to cell line #1.
P = passage; n.a. data not available (experiment not performed).
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Supplementary Figure 2. Controls for studies with human cardiac PCs. (A)
Immunofluorescence microphotographs showing expression of the indicated markers in cardiac
endothelial cells and fibroblasts used either as positive or negative control as appropriate. (B)
Control human cardiac PCs stained only with secondary antibodies Alexa-488 conjugated to
evidence the specificity of the antibodies and the low autofluorescence background of the cells.
(C) 2D-Matrigel assay: control with only cardiac PCs labelled with the red fluorescent tracker
dil. Pericytes alone fail to assemble in stable tubular networks.
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Supplementary Figure 3. EGF and bFGF control the expression of contractile VSMC
genes in human cardiac PCs. (A) Immunofluorescence images showing the expression of
VSMC markers by PCs. Cells were cultured for 10 days. (B) Transcriptional analysis of VSMC
genes in PCs and differentiated cells. Dashed line indicates coronary artery SMCs (CASMCs)
used as reference cell line. Values are expressed as fold change of CASMCs. (C) Western blot
analysis of VSMC proteins. A and B indicate cells from different donors. N=5 per group. Values
are expressed as means ± SEM. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.
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Supplementary Figure 4. VEGF and IGF-1 promote the differentiation of human PC
into VSMCs. Cells were cultured for 10 days with respective media. (A)
Immunofluorescence images showing expression of VSMC markers by PCs and derived
VSMC. (B) Transcriptional analysis of VSMC genes in PCs and differentiated cells. Dashed
line indicates coronary artery SMCs (CASMCs) used as reference cell line. Values are
expressed as fold change of CASMCs. (C)Western blot analysis of VSMC proteins. A and B
indicate cells from different donors. N=3 per group. Values are expressed as means ± SEM. *
P<0.05, ** P<0.01, *** P<0.001.
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Supplementary Figure 5. Differentiated human cardiac PCs retain the expression of
common pericyte/VSMC genes. (A) Immunofluorescence images showing expression of
NG2 and PDGFRβ by PCs and derived VSMCs. (B) Transcriptional analysis. Dashed line
indicates coronary artery SMCs (CASMCs) used as reference cell line. Values are expressed as
fold change of CASMCs. N=5 per group. ** P<0.01.
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Supplementary Figure 6. Clones of human PCs differentiate into VSMC in the absence of
EGF and bFGF, similar to the total population. The VSMC differentiation capacity of clones
(N=4) of one PC line was compared with that of the original population (N=3 different aliquots).
No significant difference was observed in the expression of the proteins between the total
population and its clones for each experimental condition. Cells were cultured for 10 days with
respective media. (A) Immunofluorescence images showing VSMC protein expression. (B)
Western blots and bar graphs showing blots quantification. For the total population, a
representative blot (one of 3 aliquots of cells used) is shown. For the 4 clones, all blots are
shown. N=3 total population, N=4 clones. Values are means ± SEM.
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Supplementary Figure 7. Human coronary artery SMCs (CASMCs) were used as a positive
control for experiments with cardiac PCs. Cells were cultured for 10 days with their growth
media in the presence or absence of GFs as indicated. Depletion of GFs and reduction of the % of
FBS were applied to stimulate the differentiation of cells into a more contractile phenotype. (A)
Immunofluorescence images showing expression of VSMC markers. (B) Transcriptional analysis of
VSMC genes in control and differentiated cells. Values are expressed as fold change of control
CASMCs. (C) Western blot analysis of VSMC proteins expression. A and B indicate two donors.
(D) Immunofluorescence images showing expression of common pericyte/VSMC markers. (E)
Transcriptional analysis of pericyte/VSMC genes in control and differentiated cells. Values are
expressed as fold change of control CASMCs. In (B-C), N=4 per group (2 donors, 2 independent
replicates each). In (D-E) N=3. All values are expressed as means ± SEM. * P<0.05 vs control cells.
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Supplementary Figure 8. Human coronary artery SMCs (CASMCs) were used as a
reference control in functional assays. (A) Gap closure migration assay. Migration time is
24h. Cells were differentiated for 10 days and then used in the migration assay. N=3. (B-C)
Expression of extracellular matrix proteins. (C) Blots and respective quantification
showing expression of Collagen I, Elastin and Fibronectin in control and differentiated
CASMCs. N=3 per group. A, B, C indicate cells from different donors. (C) Transcriptional
analysis of ECM markers. N=3. All values are displayed as means ± SEM.
preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for thisthis version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.10.376772doi: bioRxiv preprint 
Supplementary Figure 9. A) Phospho-Kinase array with human cardiac PCs. For a quick
screening of the intracellular signalling activated by EGF and bFGF but not by VEGF and IGF1
in cardiac PCs, a human phospho-Kinase protein array was performed (N=2 PCs). The array
allowed the detection of the phosphorylation of 43 kinases (R&D ARY003B). We report the
main results of the screening, the membranes and densitometry graphs. (B) A subsequent
western blot analysis confirmed the activation of EGFR-FGFR-ERK1/2 signalling by EGF and
bFGF in cardiac PCs. N=3. A, B, C are different donors.
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Supplementary Figure 10. Dose-response study to assess PD0325901 efficacy and
cytotoxicity in human cardiac PCs.
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Supplementary Figure 10. Dose-response study to assess PD0325901 efficacy and
cytotoxicity in human cardiac PCs. (A) Four increasing doses of PD0325901 were tested in
PCs up to 9 days. The DMSO corresponding to the higher concentration of the drug was used
as control. Bar graphs report the results of the MTS assay. Results for each sample is reported
as fold change of the respective vehicle. N=3 per group (4 replicates per each sample). Values
are means ± SEM. *p<0.05. The Calcein-AM/EthDIII viability assay (fluorescence
microscopy images) was performed only at the day 9. Viable cells have a green cytoplasm,
while dead cells are identified by red nuclei. HOECHST labels nuclei in blue (N=2 CPs). (B)
The drug used at a concentration of 500 nanoM was able to prevent ERK1/2 phosphorylation
in PCs (N=1) up to 24h. (C) Dose-response study to determine the minimum dose of the drug
able to prevent ERK1/2 phosphorylation up to 48h. In (B&C), cells were initially starved for
48h and pre-treated with the drug/vehicle for 1h before stimulation with EGF and bFGF. (D)
MTS assay showed that there is no significant difference in viability/metabolic activity
between cells treated with the drug and its vehicle up to 10 days. MTS optical density (OD)
values were normalised for the number of cells. N=3 per group. Values are means ± SEM.
Veh: vehicle. PD: PD0325901.
preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for thisthis version posted November 10, 2020. ; https://doi.org/10.1101/2020.11.10.376772doi: bioRxiv preprint 
Supplementary Figure 11. RNA-Seq of naïve and differentiated pericytes - effects
of PD0325901. Schematic view of the main differentially regulated hits emerging from
the pathways “Vascular smooth muscle contraction” (A) and “MAPK signalling” (B).
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Supplementary Figure 12. Expressional analyses in human cardiac PCs treated with
PD0325901. PCs were cultured either with All GFs or with No GFs or with only EGF + bFGF for
10 days, in the presence of the MEK inhibitor (250 nanoM) or its vehicle DMSO, with complete
media change every 48h. (A) VSMC gene expression analysis. The dashed line indicates coronary
artery SMCs (CASMCs) employed as reference. (B) Representative immunofluorescence images
showing common pericyte/VSMC markers at the end of the protocol. (C-D) Pericyte/VSMC (C) and
ECM (D) gene expression analysis. The dashed line indicates coronary artery SMCs (CASMCs)
employed as reference. Values are expressed as fold change of CASMCs. Values are means ± SEM.
* P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. Veh: vehicle. PD: PD0325901.
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Supplementary Figure 13. PD0325901 induces the human PC phenotypic switch into
non-mature contractile VSMCs after 3 days. PCs were cultured for 3 days in the absence
of GFs with either 250 nM PD0325901 or vehicle, with media replacement after 48h. Cells
receiving the drug upregulated intermediate contractile VSMC markers, as showed by RNA
(A) and protein (B) analyses. For RNA, dashed line indicates coronary artery SMCs
(CASMCs) used as reference cell line. Values are expressed as fold change of CASMCs. N=5
per group. For blots, A, B, C are representative of cells from 3 different donors. Values are
means ± SEM. *P<0.05, **P<0.01 vs Veh. Veh: vehicle. PD: PD0325901.
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Supplementary Figure 14. Proliferation assay with human cardiac PCs. PCs were cultured
for 10 days with either All GFs or No GFs. Media were supplemented with 250 nanoM
PD0325901 or its vehicle, with full replacement every 2 days. Cells were incubated with EdU
for 24h at the times indicated. N=3 per each group. In the immunofluorescence images, EdU is
shown in red, Calponin in green, and DAPI identifies nuclei. Values are means ± SEM. **
P<0.01, *** P<0.001, **** P<0.0001. Veh: vehicle. PD: PD0325901.
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Supplementary Figure 15. Test of the effects of cell cycle inhibition on human cardiac
PC differentiation. PCs were cultured for 10 days with All GFs. Media were supplemented
with either 250 nanoM PD0325901, or 2 mM hydroxyurea, or their vehicle (DMSO), with full
replacement every 2 days. Cells were incubated with EdU for 24h at the end of the protocol.
N=3 per each group. In the immunofluorescence images, VSMC markers and EdU are shown
in green, DAPI identifies nuclei. Veh: vehicle. PD: PD0325901. HU: hydroxyurea.
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Supplementary Figure 16. PD0325901 promotes the expression of contractile markers
in human coronary artery SMCs (CASMCs). Cells were cultured for 10 days with the
complete medium containing EGF and bFGF supplemented with either 250 nM PD0325901
or its vehicle, with media replacement every two days. Cells receiving the drug upregulated
contractile VSMC markers, as showed by immunofluorescence (A) and western blotting (B)
analyses. (C-D) Expression of pericyte/VSMC markers assessed by immunocytochemistry
and qPCR. (E) Proliferation assay. Cells were incubated with EdU for 24h starting at day 3.
EdU is shown in red, Calponin in green, and DAPI identifies nuclei in blue. In all
experiments, N=4 per each group (N=2 donors, 2 replicates per each donor). For blots, A and
B are representative of cells from 2 different donors. All values are means ± SEM. * P<0.05
vs Veh. Veh: vehicle. PD: PD0325901.
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Supplementary Figure 17. Matrigel plugs in vivo experiment. (A) Immunostaining for
Ku80 in mice hearts ruled out the cross-reactivity of the antibody with mouse tissues. (B)
Secondary antibody controls in Matrigel plugs. A secondary antibody Alexa 647 anti-
mouse was used to evidence the structure of the matrix (Matrigel matrix from mouse
sarcoma). (C) Influx of CD45+ immune/inflammatory cells in the Matrigel plugs.
Immunofluorescence images showing CD45+ cells in red and the matrix in the pseudo-
colour white. Graphs indicate the density of CD45+ cells in the plugs, expressed as
number of cells per mm2 of area. N=7 per group. Values are means ± SEM. Results are not
statistically significant. Veh: vehicle. PD: PD0325901.
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Supplementary Figure 18. Effects of PD0325901 on murine cardiac PCs. (A&B) Confocal
immunofluorescence images of mouse hearts. Arrows point to CD31neg αSMA/Calponin-neg
CD34pos PDGFRβpos PCs around arterioles (A) and capillaries (B). C: capillary. PC: pericyte.
(C) Brightfield microphotograph of expanded PCs at passage 4. (D) Antigenic profile of
expanded PCs at passage 4. N=3. Values are means ± SEM. (E&F) PC differentiation into
VSMCs using PD0325901. PCs were cultured with All GFs in the presence of PD0325901 or
its vehicle for 10 days, with full media exchange every 2 days. (E) Immunofluorescence
images show the expression of VSMC markers. (F) Blots showing a representative PC line and
graphs showing results of blots densitometry. N=4. Values are means ± SEM. *p<0.05 vs Veh.
(G) PC proliferation after 3 and 10 days of PD0325901 treatment. Immunofluorescence images
showing Ki67 in green fluorescence and graphs reporting quantitative analysis. N=3. Values
are means ± SEM. Veh: vehicle. PD: PD0325901.
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Supplementary Figure 19. Efficacy and cardiac effects of PD0325901 treatment in
healthy mice. (A) Absence of ERK1/2 phosphorylation in the hearts of PD-treated mice
was confirmed by immunofluorescence staining. Arrows point to P-ERK-positive nuclei
(green fluorescence) in the vehicle group. Cardiomyocytes are identified by the red
fluorescence of α-Sarcomeric actin (α-SA). Nuclei in blue (DAPI). (B) Western blotting
for P-ERK with total liver proteins showed systemic efficacy of the drug. (C) Apoptosis
Tunel assay. Arrows point to apoptotic nuclei (green). Cardiomyocytes are identified by
the red fluorescence of α-Sarcomeric actin (α-SA). Nuclei in blue (DAPI). Apoptotic
cardiomyocytes are expressed as a fraction of total cardiomyocytes. Apoptotic α-SA-
negative interstitial cells are expressed as number of cells per mm2 of myocardial area.
N=5 per group. Values are plotted as single values and as means ± SEM. (D) ELISA for
Cardiac Troponin T in mice plasma (n=5/group). According to guidelines for mice,
healthy animals have cTn-I < 15 ng/mL. N=5 per group. Values are plotted as single
values and as means ± SEM. (E) Analysis of the cardiomyocyte cross sectional area
(CSA). Values are reported as average CSA per each mouse. Cardiomyocytes are
identified by the red fluorescence of α-Sarcomeric actin (α-SA), Wheat Germ Agglutinin
(WGA, green) was used to identify the cardiomyocytes borders for an accurate
measurement of the cell area. Nuclei in blue (DAPI). CSA values are expressed in μm2.
N=5 mice per group. Values are plotted as single values and as means ± SEM. (F)
Cardiomyocyte density, expressed as the number of cardiomyocytes nuclei per mm2 of
myocardial area. N=5 per group. Values are plotted as single values and as means ± SEM.
(G) Example of venule identified for the luminal endothelium positivity to Endomucin. It
is possible to observe that venules VSMCs are characterised by a higher expression of
αSMA than SM-MHC. We only identified rare venules in each LV section. V: venule; A:
arteriole. (H) Analysis of capillary density in the LV. The representative microphotograph
shows capillaries in green (Isolectin-B4), arterioles in red (αSMA), and nuclei in blue
(DAPI). Bar graphs show quantification of the capillary density. N=5 per group. Values
are plotted as single values and as means ± SEM. Veh: vehicle, PD: PD0325901.
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Supplementary Figure 20. Controls for histological immunofluorescence
analyses. Staining of mouse and human frozen hearts with the only secondary
antibodies show the specificity of the secondary antibodies, as well as the low
background autofluorescence of the tissues.
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PC 1 RV 0.100 Pulmonary valve repair 14 In vitro 
PC 2 RV 1.059 Pulmonary valve repair 15 In vitro, RNA-Seq 
PC 3 RA 0.190 Atrial septal defect repair 54 In vitro, RNA-Seq, In vivo 
PC 4 RA 0.085 Atrial septal defect repair 17 In vitro, RNA-Seq, In vivo 
PC 5 RV 0.120 
Tricuspid valve replacement + 
Pulmonary valve repair 
23 In vitro, In vivo 
PC 6 RV 2.700 RV outflow tract resection 56 In vitro, In vivo 
 
Legend: 
RV right ventricle 
RA right atrium 
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Supplementary Table 2 - List of antibodies employed for analyses in human samples (including 
Matrigel plugs)  
 
  
   APPLICATION and DILUTION 
ANTIGEN HOST  COMPANY & CAT# IF (frozen) ICC WB 
CD34 Sheep R&D AF7227 1:100   
CD34 Mouse Dako M7165 1:100 1:100  
CD31 Rabbit Abcam Ab28364 1:50 1:20  
CD31 Mouse R&D BBA7 1:100   
CD146 Rabbit Abcam Ab75769  1:100  
CD45 Rat NovusBio NB100-77417 1:500   
NG2 Rabbit Millipore AB5320 1:50 1:50  
PDGFRβ Goat R&D AF385 1:50 1:50  
PDGFRα Mouse Santa Cruz sc-398206  1:100  
Vimentin Rabbit Abcam Ab92547  1:500  
αSMA  Mouse Sigma, Cy3-conjugated C6198 1:400 1:200  
αSMA  Mouse Dako, M0851  1:100 1:5000 
CALPONIN Rabbit Abcam Ab46794 1:100 1:100 1:10000 
SMMHC 
(MYH11) 
Rabbit Abcam Ab53219 1:100 1:50  
SMMHC 
(MYH11) 
Rabbit Invitrogen #702544   1:500 
Smoothelin B Rabbit Santa Cruz sc-28562  1:100 1:500 
NMMyoIIb 
(MYH10) 
Rabbit Abcam ab204358  1:200 1:1000 
SM22α Mouse Santa Cruz sc-271719  1:50 1:500 
Ku80-XRCC5 Goat R&D AF5619-SP 1:200   
Elastin Mouse Abcam ab77804   1:500 
COL1A1 Rabbit  Invitrogen #PA1-26204   1:1000 
Fibronectin Rabbit Abcam ab299   1:5000 
P-ERK1/2 Rabbit Cell Signaling #4370   1:2000 
ERK1/2 Rabbit Cell Signaling #4695   1:1000 
P-EGFR Rabbit Cell Signaling #3777   1:1000 
EGFR Rabbit Cell Signaling #4267    1:1000 
P-FGFR Rabbit Cell Signaling #3471   1:1000 
FGFR1 Rabbit Cell Signaling #9740   1:1000 
P-ELK1 Rabbit Cell Signaling #9181   1:1000 
ELK1 Rabbit Cell Signaling #9182   1:1000 
TCF21 Rabbit Abcam ab182134   1:1000 
β-Tubulin Mouse Cell Signaling #86298   1:5000 
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Supplementary Table 3 - List of antibodies employed for analyses in mouse samples 
 
  
   APPLICATION and DILUTION 
ANTIGEN HOST  COMPANY & CAT# IF (frozen) ICC WB 
CD34 Rat Abcam Ab8158 1:50 1:50  
CD31 Rabbit Abcam Ab28364 1:50 1:20  
CD146 Rabbit Abcam Ab75769  1:100  
CD45 Rat NovusBio NB100-77417 1:500   
NG2 Rabbit Millipore AB5320  1:50  
PDGFRβ Goat R&D AF385  1:50  
PDGFRβ Mouse Abcam Ab69506 1:50   
PDGFRα Mouse Santa Cruz sc-398206  1:100  
Vimentin Rabbit Abcam Ab92547  1:500  
Ki67 Rabbit Abcam Ab16667  1:200  
IB4 - I21414 Life Tech Biotin-conjugated 1:200   
αSMA Mouse Sigma, Cy3-conjugated C6198 1:400 1:400  
αSMA Mouse Sigma, A2547   1:1000 
CALPONIN Rabbit Abcam Ab46794 1:100 1:100 1:5000 
SM-MHC Rabbit Abcam Ab53219 1:100 1:50  
SMMHC  Rabbit Invitrogen #702544   1:500 
NMMyoIIb Rabbit Abcam ab204358  1:200 1:1000 
Smoothelin B Rabbit Santa Cruz sc-28562  1:100  
Endomucin Rat Thermo 14-5851-82 1:100   
α-Sarc Actin Mouse  Sigma A2172 1:100   
P-ERK1/2 Rabbit Cell Signall #4370 1:200   
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Supplementary Table 4 - List of TaqMan probes used for expressional analyses in human cells 
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Supplementary Table 5. Main markers of synthetic/contractile VSMC phenotype investigated in the 
study. 
PROTEIN GENE FUNCTION PHENOTYPE SPECIFICITY 
Non-muscle Myosin 

















Modulation of contraction 
Intermediate contractile 
Restricted to smooth muscle in adults 




Regulation of contraction 
Intermediate contractile 
Smoothelin B SMTN 
Actin associated 
Regulation of contraction 
Contractile 
Predominantly expressed in the 
vasculature of the adult. Specific to VSMC 
Smooth muscle myosin 
heavy chain  
(SM-MHC) 
MYH11 
Contractile filament  
Force generation 
Contractile  
The most specific marker of contractile 
VSMC. Rapidly lost by cultured VSMC 
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Supplementary Table 6 - Echocardiography indices (In vivo study 2 - Healthy mice) 
 Vehicle PD0325901 
 Basal Final Basal Final 
E/A ratio 1.44 ± 0.11 1.73 ± 0.19 1.53 ± 0.11 1.41 ± 0.06 
Heart rate (bpm) 441 ± 4 454 ± 4 442 ± 3 440 ± 5 
Cardiac Output (mL/min) 12.7 ± 1.1 13.8 ± 0.9 13.5 ± 1.0 11.6 ± 0.9 
LV Ejection Fraction (%) 67.9 ± 5.3 74.5 ± 2.7 69.2 ± 2.4 63.8 ± 3.0 
Fractional Shortening (%) 37.8 ± 4.3 42.6 ± 2.6 38.1 ± 1.9 33.8 ± 2.2 
Stroke volume (L) 27.8 ± 2.5 30.8 ± 2.3 29.9 ± 2.1 24.8 ± 2.3 
End Systolic Volume (μL) 15.9 ± 3.2 11.7 ± 0.5 14.7 ± 1.7 14.5 ± 2.4 
End Diastolic Volume (μL) 41.1 ± 3.9 41.1 ± 1.6 47.5 ± 2.4 39.6 ± 4.2 
LV ant wall thickness (μm) 0.72 ± 0.06 0.66 ± 0.02 0.80 ± 0.07 0.68 ± 0.06 
 
Echocardiography indices in healthy mice given vehicle or treatment. Echocardiography 
measurements were performed at baseline and after 14 days of treatment with vehicle or PD0325901. 
N=6/group. Values are means and SEM. Statistics: Two-way ANOVA was used to compare the effect 
of treatment and time and possible interaction. The two groups were balanced at baseline for all the 
measured parameters, except for CO and SV which required the use of analysis of covariance 
(ANCOVA). No significant differences attributable to treatment were observed.  
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Supplementary Table 7 - Echocardiography indices (In vivo study 3 - MI model) 
 Vehicle PD0325901 
 Basal Final Basal Final 
Heart rate (bpm) 467 ± 31 531 ± 20 448 ± 34 543 ± 21 
End Systolic Volume (μL) 15 ± 3 121 ± 32 16 ± 5 94 ± 13* 
End Diastolic Volume (μL) 62 ± 14 152 ± 26 54.3 ± 9.6 142 ± 17 
LV ant wall thickness systole (μm) 1.22 ± 0.13 0.34 ± 0.05 1.26 ± 0.10 0.49 ± 0.05** 
LV ant wall thickness diastole (μm) 0.85± 0.14 0.31 ± 0.05 0.86 ± 0.16 0.38 ± 0.05** 
LV Ejection Fraction (%) 71.6 ± 7.9 21.4 ± 8.3 72.6 ± 6.0 32.8 ± 9.3** 
Stroke volume (L) 46.9 ± 13.9 30.9 ± 8.5 38.7 ± 8.0 47.1 ± 16.2* 
Cardiac Output (mL/min) 21.6 ± 46.1 16.4 ± 4.3 18.3 ± 3.4 25.6 ± 8.8** 
 
 
Echocardiography indices in mice given vehicle or treatment after MI. Echocardiography 
measurements were performed at baseline and after MI induction + 14 days of treatment with vehicle 
or PD0325901. N=8-12/Vehicle group and 11-12/PD group. Values are means and SD, * P<0.05 and 
** P<0.01 vs. Final vehicle. Statistics: The two groups were balanced at baseline for all the measured 
parameters. 
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Extended methods 
 
Frequently used abbreviations  
bFGF basic fibroblast growth factor 
DAPI 4′,6-diamidino-2-phenylindole 
EGF epidermal growth factor 
FBS Foetal bovine serum 
IGF1 insulin-like growth factor 1 
PBS phosphate buffer saline 
PC pericyte 
PFA paraformaldehyde 
VEGF vascular endothelial growth factor 
VSMC vascular smooth muscle cell 
 
Where not otherwise stated, all chemicals were purchased from Sigma-Aldrich. 
Ethics  
Ethics regulating human studies 
This study complies with the ethical guidelines of the Declaration of Helsinki.  
Human myocardial samples (right ventricle or atrium) were discarded material from surgical repair of 
congenital heart defects (ethical approval number 15/LO/1064 from the North Somerset and South 
Bristol Research Ethics Committee). Adult patients and paediatric patients' custodians gave informed 
written consent. Donors and samples characteristics (n=6) are described in Supplementary Table 1. 
Ethics regulating animal studies 
Procedures involving animals were performed under ethical licenses from the British Home Office (PPL 
numbers 30/3373 and PFF7D0506) and in compliance with the EU Directive 2010/63/EU, and following 
approval from Animal Ethics Committee at the University of Otago (AEC10/14), New Zealand. 
Procedures were carried out according to the principles stated in the Guide for the Care and Use of 
Laboratory Animals (The Institute of Laboratory Animal Resources, 1996).  
Results are reported following the guidelines contained in the Animal Research Report of In Vivo 
Experiments (ARRIVE).  
 
Derivation of primary cultures of PCs 
Human cardiac pericytes 
Myocardial samples were collected in sterile, cold DMEM (Gibco) and processed within 24 h. The cell 
extraction protocol was as described previously1. Briefly, samples were finely minced using scissors 
and scalpel until nearly homogenous and digested with Liberase (Roche) for up to 1 hour at 37 C, with 
gentle rotation. The digest was passed through 70-, 40- and 30-μm strainers. Finally the cells were 
recovered and sorted using anti-human CD31 and anti-human CD34 microbeads (Miltenyi) to deplete 
the population of CD31+ endothelial cells and to select CD31- CD34+ cells. Cardiac PCs were cultured 
with full Endothelial Cell Growth Medium 2 (ECGM2, PromoCell) supplemented with recombinant 
human EGF (5 ng/mL), bFGF (10 ng/mL) and VEGF (0.5 ng/mL), R3-IGF1 (5 ng/mL), and 2% v/v 
FBS (all from Promocell) onto plastic plates. Cells were fed every 3 days and passaged at 90% 
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confluence. Optimal seeding density is 8,000 cells/cm2. Frozen stocks of cells were preserved with 90% 
v/v FBS + 10% v/v DMSO. Centrifuge speed and time are 300g x 10 min. Unless otherwise stated, all 
experiments were performed between passage (P) 4 and 6. All cells tested negative for mycoplasma 
(assessed using a commercial PCR assay).  
Mouse cardiac pericytes 
C57BL/6 mice (n=5) were humanely killed under schedule 1 procedure and the heart harvested for cell 
extraction. Each heart was processed separately. Briefly, samples were finely minced using scissors and 
scalpel until nearly homogenous and digested with Liberase for up to 1 hour at 37 C, with gentle rotation. 
The digest was passed through 70-, 40- and 30-μm strainers. Final cells were recovered and sorted using 
anti-mouse CD31 microbeads (Miltenyi) and anti-mouse biotinylated-CD34 (Invitrogen) followed by 
anti-biotin microbeads (Miltenyi) to deplete CD31+ endothelial cells and select CD31- CD34+ cells. 
Cardiac PCs were cultured with basal ECBM2 medium (Promocell) supplemented with 10% v/v FBS, 
recombinant mouse EGF (5 ng/mL) and bFGF (10 ng/mL) (both from Peprotech) and Amphotericin B 
(Gibco, final concentration of 0.25 μg/mL), onto plastic plates pre-coated with collagen from bovine 
skin (final concentration of 30 μg/mL). Cells were fed every 3 days and passaged at 90% confluence. 
Optimal seeding density is 20,000 cells/cm2. Frozen stocks of cells were preserved with 90% v/v FBS 
+ 10% v/v DMSO. Centrifuge speed and time are 300g x 5 min. Unless otherwise stated, all experiments 
were performed between passage 4 and 6. 
 
Cell biology studies  
Culture of cardiac fibroblasts and ECs 
Human cardiac fibroblasts were purchased from PromoCell and expanded in Fibroblast Growth Medium 
2 (FGM2, PromoCell) according to manufacturer guidelines. Human coronary artery ECs (CAECs) 
were purchased from PromoCell and and expanded in full Endothelial Cell Growth MicroVascular 
medium 2 (ECGMV2, PromoCell) according to manufacturer guidelines. All cells were used between 
passage 4 and 6. 
 
Immunocytochemistry analysis of human and mouse cells 
Cells were rinsed with PBS and fixed with 4% w/v PFA in PBS for 15 min at 20°C. After washing with 
PBS, the cells were permeabilized with 0.1% v/v Triton-X100 in PBS for 10 min at 20°C as required. 
Cells were blocked with 10% v/v FBS and incubated with the antibodies as reported in Supplementary 
tables 2&3, for 16 h at 4°C. Secondary antibodies (conjugated with Alexa 488, Alexa 568, Alexa 647) 
were all purchased from ThermoFisher Scientific and used at a dilution of 1:200, for 1 h at 20°C, in the 
dark. Nuclei were counterstained using Hoechst (1:10,000 in PBS, 3 min at 20°C). Cells were mounted 
using Fluoromount. 
2D-Matrigel in vitro angiogenesis assay 
Human coronary artery ECs (CAECs, purchased from PromoCell) were seeded on the top of Matrigel 
(Corning® Matrigel® Growth Factor Reduced Basement Membrane Matrix, cat# 356231) either alone 
(4,000 cells/well) or in co-culture with PCs (4,000 CAECs + 1,500 PC /well), using Angiogenesis μ-
Slides (IBIDI, UK). Images were snapped after 5 hours, and the total tube length per imaging field was 
measured. To assess the interaction between PCs and CAECs, PCs were labelled with the red fluorescent 
tracker Vybrant™ DiI Cell-Labeling Solution (Invitrogen). 
In experiments with only PCs, cells were seeded on the top of Matrigel, 4,000 cells/well. Images were 
snapped after 5 hours, and the total tube length per imaging field was measured. 
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Differentiation of human and mouse pericytes into VSMCs based on GFs  
For experiments aiming to assess the role of the different GFs in the VSMC differentiation of PCs, 
species-specific GFs were added to, or removed from, the culture medium as indicated in the single 
experiments. For all experimental conditions, the concentration of FBS was never modified. Cells were 
cultured for a continuous period of 10 days with full media replacement every 48 h.  
Differentiation of human coronary artery VSMCs based on GFs  
Human coronary artery smooth muscle cells (CASMCs) were purchased from Promocell and cultured 
with the Smooth Muscle Cell Growth Medium 2 (SMCGM2) according to the vendor instructions. This 
medium is supplemented with recombinant human EGF and bFGF and 5% v/v FBS. For differentiation 
experiments, EGF and bFGF were depleted from the medium and the FBS concentration reduced to 2% 
(as per the pericytes). Cells were cultured for a continuous period of 10 days with full media replacement 
every 48h.  
Pilot studies to determine PD0325901 efficacy and cytotoxicity  
PD0325901 was purchased from Sigma-Aldrich and resuspended to a final stock concentration of 500 
μM with DMSO. The compound was diluted in the culture medium as required, and DMSO used as 
vehicle control. Human PCs were cultured for ten days with growing concentrations of the drug (250 
nM, 500 nM, 1 μM, 2 μM) to determine the effects on cell viability (Calcein-AM/EthDIII staining, from 
Biotium, and MTS assay, from Promega) and decide the maximum dose usable for the in vitro and in 
vivo cell transplantation experiments. Also, western blotting analysis of ERK1/2 phosphorylation was 
used to determine the minimum dose of the compound that effectively prevents ERK1/2 activation 
following incubation with stimulating GFs.  
Differentiation of human and mouse cells into VSMCs with PD0325901  
Cells were cultured with medium supplemented with either 250 nM PD0325901 or the same volume of 
DMSO (vehicle) for ten consecutive days, with complete medium exchange every 48 h. For shorter 
experiments, cells were cultured for only three days.  
Effects of the cell cycle arrest on human PC differentiation 
To investigate if the PC differentiation was driven by the arrest of cell proliferation, cells were cultured 
with full GFs medium supplemented with 2 mM hydroxyurea for ten consecutive days, with complete 
medium exchange every other day. The same volume of DMSO was used as control. The effective 
inhibition of cell proliferation was confirmed using an EdU assay (see below). 
Single cell cloning assay with human PCs 
Live PCs at P 3 were selected on their ability to exclude propidium iodide and sorted into cultures of 
single cells using a BD Bioscience Influx sorter (BD Biosciences). These sorted cells were cultured for 
up to 4 weeks in ECGM2 full medium in separate wells of a 96-well culture plate. Clones were passaged 
into bigger plates, with culturing continuing up to P6 before being used in the VSMC differentiation 
assay with/out GFs.    
Contraction assay 
A Cell Contraction Assay (CBA-201, from Cell Biolabs) was used to assess the capacity of differentiated 
PCs to contract upon stimulation with vasoconstrictors. At the end of the 10-days differentiation 
protocol, differentiated and control PCs were embedded in collagen gels following the manufacturer 
instructions. Endothelin-1 (ET1) was used at a concentration of 0.1 μM to stimulate cell contraction. 
Butanedione Monoxime (BDM) - contraction inhibitor provided with the kit - was added to the culture 
medium at a 1:100 dilution. Gels were released and the area of the gel measured at baseline and after 
24h. Results are expressed as percentage of gel contraction. 
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Intracellular calcium flux assay 
The Fluo-4 AM fluorescent calcium indicator (ThermoFisher Scientific) was employed to study the 
intracellular calcium flux in PCs and derived VSMCs following stimulation with a vasoconstrictor 
(Endothelin-1). Cell media was replaced with a buffer made of 20 mM HEPES pH=7.4, 137 mM NaCl, 
5 mM KCl, 2 mM MgCl2, 1.8 mM CaCl2, 5.6 mM Glucose, 1 mg/mL bovine serum albumin, 0.5 mM 
NaH2PO4 and 1 mM NaHCO3. The Fluo-4 dye (2 μM) was loaded into the cells for 15 min. HOECHST 
was used to counterstain the nuclei. At the end of this incubation time, cells were stimulated with 0.1 
μM ET-1 or its vehicle. Images were recorded every 20 sec for 10 min using an INCell Analyzer 2200 
microscope (GE Healthcare) equipped with a 20 X objective. ET1 was injected in the cellular system 
after 120 sec. The intracellular calcium was measured as relative fluorescence units (RFU). Data analysis 
was carried out using the dedicated software In Cell Analyser Workstation 3.7.  
Gap closure migration assay 
The RadiusTM 96-Well Cell Migration Assay (CBA-126 from Cell Biolabs) was used to assess the 
migratory properties of cardiac PCs and CASMCs at baseline and after differentiation. Stimuli used to 
induce cell migration were recombinant human VEGF-A (10 ng/mL), human SDF1α (100 ng/mL) and 
human PDGF-BB (20 ng/mL) (all from Peprotech). Migration time was 24h, in the presence of an 
inhibitor of cells proliferation (hydroxyurea, 2 mM). Absence of stimuli served as a control for 
migration. At the end of the protocol, cells were fixed with PFA and stained for VSMC markers (α-
SMA or Calponin) and HOECHST (1:10,000 in PBS). The area of the gap not covered by cells was 
measured.  
EdU proliferation assay 
The Click-iT EdU Cell Proliferation Kit for imaging (C10337 - ThermoFisher Scientific) was used to 
assess cell proliferation. Cells were incubated with EdU for 24 h and then analyzed. Fluorescence 
staining for EdU was performed according to the manufacturer instructions.  
 
Molecular studies  
Western blotting on human and mouse total cell lysates 
Whole-cell protein lysates were collected on RIPA buffer supplemented with 1:50 proteases inhibitors 
cocktail and 1:100 phosphatases inhibitors. Cell lysates were centrifuged at 10,000 g, at 4°C, 15 min. 
After the assessment of protein concentration (BCA Protein Assay Kit, ThermoFisher Scientific), the 
supernatants were kept at -80°C. 10 to 30 μg of protein lysates were used as appropriate. Equal amounts 
of protein samples were prepared in Laemmli loading buffer, incubated for 8 min at 98°C, resolved on 
8-12% SDS-PAGE and transferred onto 0.2 μm PVDF or nitrocellulose membranes (Bio-Rad). 
Membranes were blocked using 5% w/v BSA or 5% w/v non-fat dried milk (Bio-Rad) in Tris-buffered 
saline (TBS, BioRad) supplemented with 0.05% v/v Tween-20 for 2 h at 20°C. Primary antibodies 
(listed in Supplementary Tables 2&3) were incubated for 16 h at 4°C. Either β-tubulin or β-Actin were 
used as a loading control. Anti-rabbit IgG or anti-mouse IgG HRP-conjugated antibodies were employed 
as secondary antibodies (both 1:5000, GE Healthcare). Membrane development was performed by an 
enhanced chemiluminescence-based detection method (ECL™ Prime Western Blotting Detection 
Reagent, GE Healthcare) and observed using a ChemiDoc-MP system (Bio-Rad). Proteins with similar 
MW were assessed on different gels. No more than one stripping procedure was performed on an 
individual membrane (RestoreTM Plus Western Blot Stripping Buffer; Thermo Fisher Scientific). 
Western blot data were analyzed using the ImageJ software.  
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Western blotting on mouse liver samples 
Freshly frozen liver samples were homogenized in RIPA buffer supplemented with proteases and 
phosphatases inhibitors using gentleMACS M tubes (Miltenyi). Tissue lysates were centrifuged at 
10,000 g, at 4°C, 15 min and processed as described above.  
Gene expression analysis by real-time qPCR in human PCs 
Extracted total RNA was reverse-transcribed into single-stranded cDNA using a High Capacity RNA-
to-cDNA Kit (ThermoFisher Scientific). The RT-PCR was performed using first-strand cDNA with 
TaqMan Fast Universal PCR Master Mix (ThermoFisher Scientific). The assay numbers for the 
endogenous controls and target transcripts are listed in Supplementary Table 4. TaqMan primer-probes 
were all obtained from ThermoFisher Scientific. Quantitative PCR was performed on a QuantStudioTM 
5 System (ThermoFisher). All reactions were performed in a 10 μL volume in triplicate, using 7.5 ng 
cDNA per reaction. The mRNA expression levels were determined using the 2−ΔΔCt method. 
Signalling studies in human cardiac PCs 
For the study of signalling activated by specific GFs, human PCs were cultured for 48-72 h with ECGM2 
medium depleted of all GFs. Cells were then stimulated for 30 min or 1 h with specific combinations of 
GFs (EGF+bFGF, or VEGF+IGF1) or control. The whole-cell protein lysates were then collected for 
western blotting or protein arrays. A Human Phospho-kinase array kit (R&D Systems, catalogue number 
ARY003B) was used for quick screening of 43 kinase phosphorylation sites.  
Enzyme-linked immunosorbent assay (ELISA)  
For measurement of GFs in PC-conditioned medium, confluent cells were cultured for 48 h with basal 
ECBM2 without FBS and GFs. Media was then collected, centrifuged and used in the experiments. 
Quantikine ELISA Kit anti-human VEGF, Angiopoietin-1, Angiopoietin-2 and HGF were purchased 
from R&D Systems. The amount of secreted factors was normalized to the final number of cells and 
time of incubation. Cardiac troponin I was measured in mouse plasma using the Mouse cTn-I ELISA 
kit from Elabscience (E-EL-M1203).  
Next-generation RNA-Sequencing 
A whole-transcriptome analysis was carried out in 3 human PC lines differentiated for 10 days using 
PD0325901 and compared with the respective naïve controls. CASMCs (N=2) were used for reference. 
Strand specific RNA-sequencing (seq) was performed starting from total RNA (GENEWIZ, New 
Jersey, US). 
RNA-Seq was carried out on an Illumina HiSeq platform, with a 2x150bp configuration, ~20M reads 
per sample. Sequence reads were trimmed to remove possible adapter sequences and nucleotides with 
poor quality using Trimmomatic v.0.36. The trimmed reads were mapped to the Homo sapiens GRCh38 
reference genome available on ENSEMBL using the STAR aligner v.2.5.2b, and BAM files generated. 
Unique gene hit counts were calculated by using featureCounts from the Subread package v.1.5.2. Only 
unique reads that fell within exon regions were counted. After extraction of gene hit counts, the gene hit 
counts table was used for downstream differential expression analysis. Using DESeq2, a comparison of 
gene expression between the groups of samples was performed. The Wald test was used to generate p-
values and log2 fold changes. Genes with a false discovery rate (FDR) < 0.05 and absolute log2 fold 
change > 1 were called as differentially expressed genes (DEGs) for each comparison. A gene ontology 
(GO) analysis was performed on the statistically significant set of genes by implementing the software 
GeneSCF v.1.1-p2. The goa_human GO list was used to cluster the set of genes based on their biological 
processes and determine their statistical significance.  
Extended gene annotations, hierarchical clusterings, MA-plots, pathway analyses, heatmaps were 
generated using the open-access bioinformatics softwares iDEP 9.1 
(http://bioinformatics.sdstate.edu/idep/)2 and Morpheus (https://software.broadinstitute.org/morpheus). 
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Venn diagrams were generated using InteractiVenn (http://www.interactivenn.net/index.html).3 Protein-
protein interaction networks were generated using the STRING software (https://string-
db.org/cgi/input?sessionId=bM1QcP9Hl6oN&input_page_show_search=on).  
 
In vivo studies  
Three independent studies were conducted in mice, all following randomized controlled protocols. 
 
Study 1: In vivo Matrigel plugs with human PCs 
Cold Matrigel (Corning® Matrigel® Growth Factor Reduced Basement Membrane Matrix, cat# 
356231) was mixed with human PCs (2x106) and treated with PD0325901 (500 nM) or vehicle (DMSO). 
Twelve-week-old male C57BL6/J mice (Charles River) (n=8) were injected subcutaneously into both 
abdominal flanks with 400 μL Matrigel, under anaesthesia induced by isoflurane inhalation. Seven days 
later, the animals were sacrificed, and the Matrigel plugs were harvested, fixed in 4% PFA at 4°C 
overnight, immersed in 30% w/v sucrose in PBS overnight and embedded in OCT for histological 
analyses. 15-μm thick sections were cut for immunostainings.   
 
Study 2: Administration of PD0325901 to healthy mice 
Seven-week-old female C57BL6/J mice (Charles River) (n=22) were housed in individual cages, in an 
enriched environment within a bio-secure unit under a 12 h light/dark cycle, fed with EURodent Diet 
(5LF5, LabDiet) and given drinking water ad libitum. PD0325901 was given orally and voluntarily each 
day by inclusion of the compound in sugar-free strawberry-flavoured jelly, as previously described.4, 5  
PD0325901-jelly preparation. 
The jelly was prepared every 2 days, stored at 4  ͦC and used within 48 h to ensure the stability of the 
drug. Mice were conditioned to eat the jelly for 5 days (twice daily) before the start of the 14-day 
experimental protocol. PD0325901 was given to mice (n=11) at 10 mg/kg body weight once daily; it 
was dissolved in DMSO and incorporated within the jelly. The control group (n=11) received DMSO-
jelly. 50 μL DMSO/drug were dissolved in a final volume of 4 mL jelly, so that the final dose of DMSO 
was not toxic for the animals. Mice were given jelly 8 μL/g body weight. Individual housing was 
necessary to observe jelly consumption.  
All of the mice ate the entire jelly during the experiment; therefore none were  excluded from the study. 
A cohort of mice (n=6/group) underwent echocardiography at baseline and at the end of the protocol. 
Cardiac dimensional and functional parameters were measured with using a high-frequency, high-
resolution, 3D echocardiography system (Vevo3100, Fujifilm, VisualSonics) using an MX550D 
transducer, with mice under isoflurane anaesthesia to maintain the heart rate at 450 bpm. Animals were 
terminated 2-to-4 hours after the last treatment (jelly administration). Hearts (n=5/group) were stopped 
in diastole using KCl, perfusion-fixed (PBS-EDTA followed by 4% PFA) and harvested. Hearts were 
then weighed and fixed in 4% w/v PFA at 4°C overnight, immersed in 30% w/v sucrose in PBS 
overnight and embedded in OCT (Tissue-Tek® O.C.T. Compound, VWR) for cryopreservation and 
histological analyses. 5-μm thick sections were cut for immunostainings. Livers (n=5/group) were 
harvested and freshly frozen in liquid N2 for molecular biology. Blood (n=5/group) was collected with 
EDTA for plasma separation and analysis of circulating biomarkers.  
Blood flow measurement. 
Left ventricle myocardial blood flow was assessed in the same mice that had undergone 
echocardiography (n=6 mice/group), according to previously published protocols.6-8 Briefly, 
carboxylate-modified green-fluorescent microspheres (cat# F8813, Invitrogen, 0.5μm diameter) were 
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injected in the left ventricle cavity over one minute, for a total volume of 200 μL, and flushed with 150 
μL of warmed saline. Reference blood samples were obtained from the descending aorta over a time of  
2 min. The left ventricle, kidneys and reference blood were collected for subsequent recovery of 
microspheres and fluorescence reading. The weigth of the organ post-harvest was recorded. Regional 
blood flow was calculated as the absolute blood flow in ml/min/g of tissue using the formula described 
earlier.7, 8 The Kidneys were analyzed to confirm the uniform distribution of fluorescent microspheres 
in the systemic circulation. 
 
Study 3: Administration of PD0325901 in a mouse model of myocardial infarction (MI) 
This study was conducted in 8 weeks old C57/Bl6 mice (Hercus). Mice were acclimatized with sugar-
free strawberry-flavoured jelly (prepared as above) for five days before surgery. MI was induced by 
permanent ligation of the left anterior descending coronary artery (LAD) as described before.7 In brief, 
following anaesthesia (2,2,2 tribromo ethanol, 0.3gm/kg, i.p.) and artificial ventilation, the chest cavity 
was opened and, after careful dissection of the pericardium, LAD was located and permanently ligated 
using a 7-0 silk suture. After confirming for the absence of bleeding, chest cavity was closed in layers. 
Animals were allowed to recover for at least 4 hours before returning to the housing unit. Mice were 
monitored twice a day for the first 5 days post-surgery and thereon once every day. All the mice received 
analgesic and antibiotic from just before the surgery for the next 3 days. Following 3 days of recovery 
post-MI, mice were randomized to receive the sugar-free strawberry-flavoured jelly with or without 
PD0325901 for next 14 days. Cardiac function was assessed using echocardiography measurement at 
baseline (before MI) and at 14 days post-MI. At the end of the treatment period and following 
echocardiography, and under anaesthesia, heart were stopped  in diastole using KCl, and ventricular 
tissue was collected following perfusion-fixation with 4% PFA. The collected tissue were used to 
determine the effect of PD0325901 on angiogenesis and fibrotic remodelling following MI as described 
below. 
 
Histology on human and mouse tissues 
Histological procedures 
Human myocardial samples were fixed in 4% PFA at 4°C overnight, immersed in 30% w/v sucrose in 
PBS overnight and embedded in OCT for cryopreservation and histological analyses. 5-μm thick 
sections were cut for identification of cardiac PCs in situ. Mice samples were prepared as described 
above. Human and mouse frozen sections were post-fixed and permeabilized with ice-cold acetone 
(VWR) for 5 min at -20 °C, and let air dry for 30 min. Sections were rehydrated with PBS for 10 min. 
For P-ERK staining, the protocol required permeabilization with ice-cold methanol (VWR) for 10 min 
at -20 °C. Tissue sections were blocked with 5% v/v FBS or normal goat serum (as appropriate) and 
incubated with primary antibodies for 16h at 4°C.  
To determine the capillary density, 5-μm thick cryosections were incubated with biotinylated isolectin 
B4 (Griffonia Simplicifolia Lectin I (GSL I) isolectin B4, Biotinylated, B-1205, Vector Laboratories) 
to stain endothelial cells overnight at 4°C. Antibodies are reported in the Supplementary Tables 2&3. 
Secondary antibodies (Alexa 488-, Alexa 568-, Alexa 647, streptavidin Alexa-488-conjugated) were all 
purchased from ThermoFisher Scientific and used at a dilution of 1:200, for 1h at 20°C except for 
streptavidin Alexa-488 to detect endothelial cells which was incubated for 4h at 20°C in the dark. To 
determine the arteriole density For smooth muscle cells identification to determine the arteriole density, 
5-μm thick cryosections were incubated with Cy3 conjugated monoclonal anti-alpha smooth muscle 
actin for 4 hrs at room temperature along with the streptavidin Alexa-488. Slides were mounted using 
ProLong™ Gold Antifade Mountant with DAPI (ThermoFisher Scientific). 
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For the analysis of apoptosis in mice hearts, the ApopTag® Fluorescein In Situ Apoptosis Detection Kit 
was employed, following manufacturer instructions.  
Alexa-488 conjugated wheat germ agglutinin (WGA) (ThermoFisher) (30 min, 1:200 dilution) was used 
to identify cardiomyocytes borders for morphometric analyses.  
To identify the fibrotic tissue in the samples from the MI study, Azan Mallory staining was performed 
as previously described.7, 9 
Whenever new antibodies, not previously employed and tested in our lab, were adopted, the specificity 
of the antibodies was tested on positive (and negative where available) control samples following the 
manufacturer's guidelines. The specificity of the secondary antibodies Alexa-Fluor conjugated, as well 
as the background autofluorescence of the tissues, are shown in Supplementary Figure 20. 
 
Histological analyses of human and mouse tissues 
Study 1 - PC-Matrigel plugs 
• Expression of VSMC markers by human PCs: The Ku80-XRCC5 antigen was utilized to 
recognize the human cells. Cytoplasmatic staining ruled out cell senescence.10, 11 Antibodies anti-
αSMA, Calponin and SM-MHC were used to recognize VSMC proteins. Results are expressed 
as percentage of human PCs expressing the indicated VSMC marker. N=2 sections were analyzed 
per each sample. 
• Infiltration of immune/inflammatory cells: an antibody anti-CD45 was employed to assess the 
presence of immune cells within the plugs. Results are expressed as number of CD45+ cells per 
mm2 of plug area. N=2 sections were analyzed per each sample. 
 
Study 2 - Healthy mice 
• Arteriole density: Small and large arterioles density was expressed as the number of arterioles per 
mm2. Arterioles were classified as small (< 20μm) and large (> 20μm) according to their lumen 
size. Venules were recognized for positivity to Endomucin and excluded from the analysis.12 All 
arterioles present in an entire section of LV was analyzed per each mouse. Considering we could 
detect only rare venous vessels with a very bright αSMA fluorescence like arteries, and this 
number was uniform across the two groups, the Endomucin marker was not used for all the 
following analyses. Normally, defining the microscope fluorescence settings to identify arteries, 
veins are not detected due to the remarkably low levels of fluorescence.  
• Arterial VSMC maturation: this was evaluated as the ratio between the areas occupied by 
SMMHC and αSMA. Briefly, RGB images, acquired keeping the microscope settings unvaried, 
were segmented into three grey-scale channels using ImageJ, the background subtracted, and an 
automatic threshold was calculated and applied for each channel using the ImageJ built-in 
algorithms to measure the area of the green and red signal for each vessel. Final data are expressed 
as a volume fraction between the areas occupied by SMMHC and αSMA. Ten random small and 
large arterioles were analyzed per each mouse, for a final N=50 total arterioles/group. Per each 
mouse, the average of all measurements was calculated.   
• Coverage of arterioles with CD34pos cells: this was measured as the ratio between the areas 
occupied by perivascular CD34 and αSMA of the arterial wall, with the same procedure described 
above. N=10 random small and large arterioles were analyzed per each mouse, for a final N=50 
total arterioles/group. Per each mouse, the average of all measurements was calculated.   
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• Arterioles surrounded by CD34pos cells: this was expressed as a percentage of total arterioles. All 
arterioles included in an entire section of LV were analyzed per each mouse.  
• Capillary density: this was evaluated in ten random fields (snapped using a 10x objective) in 
which capillaries were transversally oriented. Per each mouse, it was expressed as the number of 
capillaries per square millimetre of myocardial tissue.  
• Cardiomyocytes cross-sectional area (CSA): the CSA was measured in cardiomyocytes in which 
the nucleus was centrally located within the cell. All suitable cardiomyocytes were evaluated in 
two entire LV sections. Data are reported as the average CSA per each mouse, and as a distribution 
of all individual CSA.  
• Cardiomyocytes density: the number of cardiomyocytes nuclei was counted in 10 random fields, 
snapped at 100x, from two LV sections. Results are expressed as number of cardiomyocyte nuclei 
per mm2 of myocardial area. 
• Cardiomyocytes apoptosis: Apoptotic cardiomyocytes were expressed as the number of Tunel+ 
cardiomyocytes per 100,000 cardiomyocytes. Two entire sections of the LV were analyzed.  
• Interstitial cells apoptosis: Tunel+ αSA-negative interstitial cells were expressed as the number 
of cells per square millimetre of myocardial area. 
 
Study 3 - Mouse MI model 
• Capillary and arteriole density: capillaries and arterioles were calculated in 6 fields at X200 
magnification and the final data expressed as the number of capillaries or arterioles per square 
millimetre. Quantification was performed in the peri-infarct area and in the remote myocardium 
separately. Arterioles were categorised according to their luminal size.   
• Infarct size: Data were expressed as the percentage of LV occupied by the fibrotic scar (Azan 
Mallory staining). A whole LV section was analysed per each mouse. 
 
Microscopy equipment and post-imaging analysis 
Most of the analyses were carried out on photomicrographs obtained using an Axio Observer Z1 (Zeiss) 
equipped with 10 X and 20 X objectives. For confocal imaging, we used a Leica SP5-II AOBS multi-
laser confocal laser scanning microscope attached to a Leica DM I6000 inverted epifluorescence 
microscope (Leica Microsystems), equipped with a 20 X, 40 X and 63 X immersion oil objectives. 
Images processing was performed using the dedicated ZEN PRO and Leica LAS X software, and 
Photoshop CC (Adobe). Images analyses were performed using the open-access ImageJ (NIH) software. 




Continuous variables are presented as means ± standard error of the mean (SEM) or standard deviation 
(SD) of independent samples and/or as individual values. The D'Agostino-Pearson and Kolmogorov–
Smirnov normality tests were used to check for normal distribution when applicable. Continuous 
variables normally distributed were compared using the Student's t-test (two-group comparison) or one-
way analysis of variance (ANOVA; for multiple group comparisons). Two-way ANOVA analyses were 
used to compare the mean differences between groups when appropriate. Non-parametric tests, 
including the Mann–Whitney U test (two-group comparison) and the Kruskal-Wallis test (multiple 
group comparison) were used to compare data not normally distributed. Post-hoc analyses included 
Tukey and Dunn tests, as appropriate. Echocardiography parameters (baseline and final assessed in the 
same animal) were compared using paired tests; for all other analyses, unpaired tests were applied. For 
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in vivo studies, post-hoc analyses of outcomes were conducted according to the intention-to-treat 
principle. In Study 2, when baseline echo measurements were found to differ between groups, the 
analysis of covariance (ANCOVA) was used, as it provides the optimum statistical analysis in terms of 
bias, precision, and statistical power. In Study 3, where final values were missing due to the early animal 
mortality, we used a mixed-effects model to analyze repeated measures data with missing values 
(available in GraphPad Prism 8.0). Significance was assumed when p ≤ 0.05. Analyses were performed 
using GraphPad Prism 6.0 and 8.0.  
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